Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Infliximab
Remicade
Routinely available
NICE (TA383 (SMC 101/04))
01/01/2006
Indication
For the treatment of ankylosing spondylitis
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
Solution for infusion
Comments
January 2006 - Added to the Formulary as second choice for the treatment of ankylosing spondylitis, for Specialist Use only. February 2016 - NICE MTA advice: SMC advice 101/04 is superseded by NICE TA383. July 2019 (as per LJF) - Routinely available in line with national guidance. Included in the LJF, for Specialist Use only.
Link to Advice
Advice Published
01/02/2016